Regenxbio (RGNX) Reports Q3 Loss, Tops Revenue Estimates

Regenxbio (RGNX) came out with a quarterly loss of $1.17 per share versus the Zacks Consensus Estimate of a loss of $1.16. This compares to loss of $1.41 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -0.86%. A quarter ago, it was expected that this biotechnology company would post a loss of $1.29 per share when it actually produced a loss of $1.05, delivering a surprise of 18.60%.Over the last four quarters, the company has ...